Hoth Therapeutics, Inc. Recorded Big Gain

Hoth Therapeutics, Inc. (HOTH:NASDAQ) jumped higher at $10.72, representing a gain of 143.6%. On Thu, Dec 29, 2022, HOTH:NASDAQ hit a New 2-Week High of $10.72. The stock got featured on our News Catalysts scanner on Thu, Dec 29, 2022 at 11:15 AM in the 'BIOTECH' category. From Thu, Dec 15, 2022, the stock recorded 55.56% Up Days and 70.00% Green Days
About Hoth Therapeutics, Inc. (HOTH:NASDAQ)
Hoth Therapeutics Inc is a development stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Top 10 Gainers:
- Hoth Therapeutics, Inc. (HOTH:NASDAQ), 143.64%
- Kala Pharmaceuticals, Inc. (KALA:NASDAQ), 99.04%
- Palisade Bio Inc. (PALI:NASDAQ), 77.9%
- SatixFy Communications Ltd. (SATX:NYSEMKT), 67.68%
- First Wave BioPharma Inc. (FWBI:NASDAQ), 61.22%
- Baudax Bio, Inc. (BXRX:NASDAQ), 56.09%
- Quotient Limited (QTNT:NASDAQ), 54.13%
- Starry Group Holdings Inc. Class A (STRY:NYSE), 49.75%
- Mercurity Fintech Holding Inc. (MFH:NASDAQ), 45.57%
- Sonendo Inc. (SONX:NYSE), 39.11%